Research graph
References from Transposon Vectors Enable Accelerated Development of Cellular Assay Platforms for the Identification and Characterization of Anti-Viral Small-Molecule Cell-Entry Inhibitors and Neutralizing Antibodies. Local targets link to admitted publications; unresolved targets remain external evidence.
Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis
10.1016/j.virusres.2014.11.021 · 2015 · External reference
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
10.1016/j.cell.2020.02.052 · 2020 · External reference
Wild-type human coronaviruses prefer cell-surface TMPRSS2 to endosomal cathepsins for cell entry
10.1016/j.virol.2017.11.012 · 2018 · External reference
Compound screen identifies the small molecule Q34 as an inhibitor of SARS-CoV-2 infection
10.1016/j.isci.2021.103684 · 2022 · External reference
10.3390/microorganisms13081785
10.3390/microorganisms13081785 · External reference
Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists
10.1128/jvi.01337-15 · 2015 · External reference
Therapeutic Monoclonal Antibodies for Ebola Virus Infection Derived from Vaccinated Humans
10.1016/j.celrep.2019.03.020 · 2019 · External reference
Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin
10.1126/science.aaq0620 · 2018 · External reference
10.3390/v17070989
10.3390/v17070989 · External reference
10.3389/fimmu.2021.653189
10.3389/fimmu.2021.653189 · External reference
10.3390/v13071279
10.3390/v13071279 · External reference
Infection of RAW 264.7 Cells by Murine Leukemia Virus-Derived Retroviral Pseudotype Expressing the Envelope Glycoprotein of EBOV Is Enhanced by Antibodies
10.1002/jmv.70702 · 2025 · External reference
Murine Leukemia Virus (MLV)-based Coronavirus Spike-pseudotyped Particle Production and Infection
2016 · External reference
Pseudotyping of murine leukemia virus with the envelope glycoproteins of HIV generates a retroviral vector with specificity of infection for CD4-expressing cells
10.1073/pnas.94.16.8640 · 1997 · External reference
Identification of a human respiratory syncytial virus cell entry inhibitor by using a novel lentiviral pseudotype system
10.1128/jvi.03074-15 · 2016 · External reference
Truncation of the human immunodeficiency virus type 1 envelope glycoprotein allows efficient pseudotyping of Moloney murine leukemia virus particles and gene transfer into CD4+ cells
10.1128/jvi.71.4.3341-3345.1997 · 1997 · External reference
Unresolved reference
External reference
10.3390/cancers12041000
10.3390/cancers12041000 · External reference
10.3390/ijms241914487
10.3390/ijms241914487 · External reference
Validation of an MLV-based SARS-CoV-2 pseudovirus neutralization assay substantiates L455S-mediated antibody escape
10.1038/s41598-026-53146-7 · 2026 · External reference
Production of retroviral vectors in continuous high cell density culture
10.1007/s00253-023-12689-9 · 2023 · External reference
Rapid establishment of stable retroviral packaging cells and recombinant susceptible target cell lines employing novel transposon vectors derived from Sleeping Beauty
10.1016/j.virol.2019.02.014 · 2019 · External reference
Establishment of a novel stable human suspension packaging cell line producing ecotropic retroviral MLV(PVC-211) vectors efficiently transducing murine hematopoietic stem and progenitor cells
10.1016/j.jviromet.2021.114243 · 2021 · External reference
10.3389/fbioe.2023.1076524
10.3389/fbioe.2023.1076524 · External reference
10.3390/ijms26178289
10.3390/ijms26178289 · External reference
Quantitative assays reveal cell fusion at minimal levels of SARS-CoV-2 spike protein and fusion from without
10.1016/j.isci.2021.102170 · 2021 · External reference
Author Correction: Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
10.1038/s41467-021-22614-1 · 2021 · External reference
10.3390/biotech15020038
10.3390/biotech15020038 · External reference
Advanced Establishment of Stable Recombinant Human Suspension Cell Lines Using Genotype-Phenotype Coupling Transposon Vectors
10.1007/978-1-4939-9853-1_20 · 2020 · External reference
Transgene Expression and Transposition Efficiency of Two-Component Sleeping Beauty Transposon Vector Systems Utilizing Plasmid or mRNA Encoding the Transposase
10.1007/s12033-022-00642-6 · 2023 · External reference
Production and titration of lentiviral vectors
2007 · External reference
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
10.1016/j.cell.2020.06.043 · 2020 · External reference
SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity
10.1038/s41467-020-19808-4 · 2020 · External reference
SARS-coronavirus-2 replication in Vero E6 cells: Replication kinetics, rapid adaptation and cytopathology
10.1099/jgv.0.001453 · 2020 · External reference
A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells
10.1016/j.molcel.2020.04.022 · 2020 · External reference
SARS-CoV-2 Spike Furin Cleavage Site and S2′ Basic Residues Modulate the Entry Process in a Host Cell-Dependent Manner
10.1128/jvi.00474-22 · 2022 · External reference
Optimized Pseudotyping Conditions for the SARS-CoV-2 Spike Glycoprotein
10.1128/jvi.01062-20 · 2020 · External reference
10.1101/2020.08.28.271163
10.1101/2020.08.28.271163 · External reference
Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: Implication for development of RBD protein as a viral attachment inhibitor and vaccine
10.1038/s41423-020-0400-4 · 2020 · External reference
Structure and activity of human TMPRSS2 protease implicated in SARS-CoV-2 activation
10.1038/s41589-022-01059-7 · 2022 · External reference
10.3390/pharmaceutics15051412
10.3390/pharmaceutics15051412 · External reference
Research progress in methods for detecting neutralizing antibodies against SARS-CoV-2
10.1016/j.ab.2023.115199 · 2023 · External reference
Effective screening of SARS-CoV-2 neutralizing antibodies in patient serum using lentivirus particles pseudotyped with SARS-CoV-2 spike glycoprotein
10.1038/s41598-020-76135-w · 2020 · External reference
Pseudoviruses, a safer toolbox for vaccine development against enveloped viruses
10.1080/14760584.2023.2299380 · 2024 · External reference
Infection of RAW 264.7 Cells by Murine Leukemia Virus-Derived Retroviral Pseudotype Expressing the Envelope Glycoprotein of EBOV Is Enhanced by Antibodies
10.1002/jmv.70702 · ExternalCitation · doi-reference
Advanced Establishment of Stable Recombinant Human Suspension Cell Lines Using Genotype-Phenotype Coupling Transposon Vectors
10.1007/978-1-4939-9853-1_20 · ExternalCitation · doi-reference
Production of retroviral vectors in continuous high cell density culture
10.1007/s00253-023-12689-9 · ExternalCitation · doi-reference
Transgene Expression and Transposition Efficiency of Two-Component Sleeping Beauty Transposon Vector Systems Utilizing Plasmid or mRNA Encoding the Transposase
10.1007/s12033-022-00642-6 · ExternalCitation · doi-reference
Research progress in methods for detecting neutralizing antibodies against SARS-CoV-2
10.1016/j.ab.2023.115199 · ExternalCitation · doi-reference
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
10.1016/j.cell.2020.02.052 · ExternalCitation · doi-reference
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
10.1016/j.cell.2020.06.043 · ExternalCitation · doi-reference
Therapeutic Monoclonal Antibodies for Ebola Virus Infection Derived from Vaccinated Humans
10.1016/j.celrep.2019.03.020 · ExternalCitation · doi-reference
Quantitative assays reveal cell fusion at minimal levels of SARS-CoV-2 spike protein and fusion from without
10.1016/j.isci.2021.102170 · ExternalCitation · doi-reference
Compound screen identifies the small molecule Q34 as an inhibitor of SARS-CoV-2 infection
10.1016/j.isci.2021.103684 · ExternalCitation · doi-reference
Establishment of a novel stable human suspension packaging cell line producing ecotropic retroviral MLV(PVC-211) vectors efficiently transducing murine hematopoietic stem and progenitor cells
10.1016/j.jviromet.2021.114243 · ExternalCitation · doi-reference
A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells
10.1016/j.molcel.2020.04.022 · ExternalCitation · doi-reference
Wild-type human coronaviruses prefer cell-surface TMPRSS2 to endosomal cathepsins for cell entry
10.1016/j.virol.2017.11.012 · ExternalCitation · doi-reference
Rapid establishment of stable retroviral packaging cells and recombinant susceptible target cell lines employing novel transposon vectors derived from Sleeping Beauty
10.1016/j.virol.2019.02.014 · ExternalCitation · doi-reference
Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis
10.1016/j.virusres.2014.11.021 · ExternalCitation · doi-reference
Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: Implication for development of RBD protein as a viral attachment inhibitor and vaccine
10.1038/s41423-020-0400-4 · ExternalCitation · doi-reference
SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity
10.1038/s41467-020-19808-4 · ExternalCitation · doi-reference
Author Correction: Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
10.1038/s41467-021-22614-1 · ExternalCitation · doi-reference
Structure and activity of human TMPRSS2 protease implicated in SARS-CoV-2 activation
10.1038/s41589-022-01059-7 · ExternalCitation · doi-reference
Effective screening of SARS-CoV-2 neutralizing antibodies in patient serum using lentivirus particles pseudotyped with SARS-CoV-2 spike glycoprotein
10.1038/s41598-020-76135-w · ExternalCitation · doi-reference
Validation of an MLV-based SARS-CoV-2 pseudovirus neutralization assay substantiates L455S-mediated antibody escape
10.1038/s41598-026-53146-7 · ExternalCitation · doi-reference
Pseudotyping of murine leukemia virus with the envelope glycoproteins of HIV generates a retroviral vector with specificity of infection for CD4-expressing cells
10.1073/pnas.94.16.8640 · ExternalCitation · doi-reference
Pseudoviruses, a safer toolbox for vaccine development against enveloped viruses
10.1080/14760584.2023.2299380 · ExternalCitation · doi-reference
SARS-coronavirus-2 replication in Vero E6 cells: Replication kinetics, rapid adaptation and cytopathology
10.1099/jgv.0.001453 · ExternalCitation · doi-reference
10.1101/2020.08.28.271163
10.1101/2020.08.28.271163 · ExternalCitation · doi-reference
Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin
10.1126/science.aaq0620 · ExternalCitation · doi-reference
SARS-CoV-2 Spike Furin Cleavage Site and S2′ Basic Residues Modulate the Entry Process in a Host Cell-Dependent Manner
10.1128/jvi.00474-22 · ExternalCitation · doi-reference
Optimized Pseudotyping Conditions for the SARS-CoV-2 Spike Glycoprotein
10.1128/jvi.01062-20 · ExternalCitation · doi-reference
Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists
10.1128/jvi.01337-15 · ExternalCitation · doi-reference
Identification of a human respiratory syncytial virus cell entry inhibitor by using a novel lentiviral pseudotype system
10.1128/jvi.03074-15 · ExternalCitation · doi-reference
Truncation of the human immunodeficiency virus type 1 envelope glycoprotein allows efficient pseudotyping of Moloney murine leukemia virus particles and gene transfer into CD4+ cells
10.1128/jvi.71.4.3341-3345.1997 · ExternalCitation · doi-reference
10.3389/fbioe.2023.1076524
10.3389/fbioe.2023.1076524 · ExternalCitation · doi-reference
10.3389/fimmu.2021.653189
10.3389/fimmu.2021.653189 · ExternalCitation · doi-reference
10.3390/biotech15020038
10.3390/biotech15020038 · ExternalCitation · doi-reference
10.3390/cancers12041000
10.3390/cancers12041000 · ExternalCitation · doi-reference
10.3390/ijms241914487
10.3390/ijms241914487 · ExternalCitation · doi-reference
10.3390/ijms26178289
10.3390/ijms26178289 · ExternalCitation · doi-reference
10.3390/microorganisms13081785
10.3390/microorganisms13081785 · ExternalCitation · doi-reference
10.3390/pharmaceutics15051412
10.3390/pharmaceutics15051412 · ExternalCitation · doi-reference
10.3390/v13071279
10.3390/v13071279 · ExternalCitation · doi-reference
10.3390/v17070989
10.3390/v17070989 · ExternalCitation · doi-reference
